Regulus Therapeutics Inc (NASDAQ:RGLS)

12.85
Delayed Data
As of May 22
 +0.10 / +0.78%
Today’s Change
6.08
Today|||52-Week Range
25.60
-19.89%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$655.6M

Company Description

Regulus Therapeutics, Inc. discovers and develops pharmaceutical products. It is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a broad range of diseases. The company intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases. It is developing RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy, and RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection. Regulus Therapeutics was founded in September 2007 and is headquartered in San Diego, CA.

Contact Information

Regulus Therapeutics, Inc.
3545 John Hopkins Court
San Diego California 92121-1121
P:(858) 202-6300
Investor Relations:
(858) 202-6321

Employees

Shareholders

Individual stakeholders41.80%
Other institutional32.43%
Mutual fund holders31.80%

Top Executives

Kleanthis G. XanthopoulosPresident, Chief Executive Officer & Director
Daniel R. ChevallardVice President-Finance & Accounting
Neil W. GibsonChief Scientific Officer
Paul C. GrintChief Medical Officer
Amy ConradDirector-Investor Relations & Communications

To view my watchlist

Not a member yet?

Sign up now for a free account